Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1


  1. Hamadani M, Craig M, Awan FT, Devine SM . How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 1259–1268.

    Article  CAS  Google Scholar 

  2. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  3. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.

    Article  CAS  Google Scholar 

  4. Extermann M . Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181–200.

    Article  CAS  Google Scholar 

  5. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M . Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission-a review from the Acute Leukemia Working Party of the EBMT. Haematologica 2015; 100: 859–869.

    Article  Google Scholar 

  6. Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia 2015; 29: 1478–1484.

    Article  CAS  Google Scholar 

  7. Platzbecker U . Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. Hematology Am Soc Hematol Educ Program 2013; 2013: 522–528.

    Article  Google Scholar 

  8. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333–1338.

    Article  CAS  Google Scholar 

  9. Bolanos-Meade JKJ, Reshef R . A Multicenter Phase II Trial Randomizing Novel Approaches for Graft-versus-host Disease Prevention Compared to Contemporary Controls (1203). Available at Accessed on 19 January 2015.

  10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to A Nazha.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nazha, A., Rybicki, L., Abounader, D. et al. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. Bone Marrow Transplant 51, 1642–1643 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links